The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index; 21 of the 46 sources its claims cite were checked for support.
A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice
Open accessAbstract
Toxoplasma gondii ( T. gondii ) can infect almost all warm-blooded animals and is a major threat to global public health. Currently, there is no effective drug or vaccine for T. gondii . In this study, bioinformatics analysis on B and T cell epitopes revealed that TGGT1_316290 (TG290) had superior effects compared with the surface antigen 1 (SAG1). TG290 mRNA-LNP was constructed through the Lipid Nanoparticle (LNP) technology and intramuscularly injected into the BALB/c mice, and its immunogenicity and efficacy were explored. Analysis of antibodies, cytokines (IFN-γ, IL-12, IL-4, and IL-10), lymphocytes proliferation, cytotoxic T lymphocyte activity, dendritic cell (DC) maturation, as well as CD4 + and CD8 + T lymphocytes revealed that TG290 mRNA-LNP induced humoral and cellular immune responses in vaccinated mice. Furthermore, T-Box 21 (T-bet), nuclear factor kappa B (NF-kB) p65, and interferon regulatory factor 8 (IRF8) subunit were over-expressed in the TG290 mRNA-LNP-immunized group. The survival time of mice injected with TG290 mRNA-LNP was significantly longer (18.7 ± 3 days) compared with the survival of mice of the control groups ( p < 0.0001). In addition, adoptive immunization using 300 μl serum and lymphocytes (5*10 7 ) of mice immunized with TG290 mRNA-LNP significantly prolonged the survival time of these mice. This study demonstrates that TG290 mRNA-LNP induces specific immune response against T. gondii and may be a potential toxoplasmosis vaccine candidate for this infection.
Overview
CoChat Summary
## TL;DR
TG290 (TGGT1_316290) mRNA-LNP vaccination in BALB/c mice induced both humoral and cellular immune responses against *Toxoplasma gondii* and prolonged survival after lethal RH-strain challenge. The study presents TG290 as a promising toxoplasmosis vaccine candidate based on epitope prediction, in vitro expression, and mouse immunization experiments.
## Key findings
- Bioinformatics analysis suggested TG290 had better predicted linear B-cell epitope properties than SAG1, with higher surface probability, antigenic index, flexibility, and hydrophilicity; for T-cell epitopes, TG290 showed lower predicted IC50 values for H2-Iad and H2-Ied than SAG1.
- The TG290 mRNA-LNP formulation had an encapsulation efficiency of 95.8% and induced TG290 protein expression in transfected HEK293 cells and C2C12 cells.
- Vaccinated mice had significantly higher TG290-specific antibodies than controls: total IgG increased with the number of injections, and IgG1 and IgG2a were both elevated; the paper reports IgG2a at 0.86 ± 0.01 and IgG1 at 0.47 ± 0.01.
- Immune readouts were increased in vaccinated mice, including IFN-γ (874.6 ± 27.1 pg/ml), IL-12 (790.6 ± 9.8 pg/ml), IL-4 (138.8 ± 1.7 pg/ml), IL-10 (265.9 ± 2.3 pg/ml), lymphocyte proliferation (SI 2.1 ± 0.06), CTL activity, CD4+ and CD8+ T cells, and DC markers CD83/CD86 and MHC-I/MHC-II.
- After challenge with 100 RH tachyzoites, TG290 mRNA-LNP-vaccinated mice survived longer (18.5 ± 3 days; abstract also reports 18.7 ± 3 days) than blank and LNP controls, which died within 8 days; adoptive transfer of immune serum or splenocytes also prolonged survival (11.9 ± 2.6 days and 14.4 ± 2.5 days, respectively).
## Methods
- Design: preclinical vaccine study combining epitope prediction, mRNA-LNP vaccine construction, in vitro expression testing, mouse immunization, immune assays, and lethal parasite challenge.
- Sample/data: seven-week-old male BALB/c mice (n = 60) split into TG290 mRNA-LNP, empty LNP, and blank groups; additional naive mice (n = 30) were used for adoptive transfer experiments. HEK293, C2C12, Vero, and Sp2/0 cells were used for transfection/expression and CTL assays.
- Main analysis: ELISA for TG290-specific antibodies, cytokine ELISAs, lymphocyte proliferation assays, CTL assays, flow cytometry for T cells and dendritic-cell markers, qRT-PCR/western blot for IRF8, T-bet, and NF-κB p65, and survival analysis using log-rank tests.
## Limitations
- The paper states that all vaccinated and adoptively immunized mice eventually died after lethal RH challenge, so the vaccine prolonged survival but did not provide complete protection.
- Evident from the text: the efficacy was tested only in female/male? male BALB/c mice are explicitly mentioned here, under a single mouse strain and against the highly virulent RH strain, so generalizability to other hosts, parasite strains, or protective endpoints is not established.
- Evident from the text: the study is preclinical and does not report human data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
18 Valid · 2 Not valid · 22 Not checked · 51 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“there is no safe and effective vaccine for T. gondii (Chu and Quan, 2021).”
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Introduction
What the sources say
- Partly supportedcites Chu and Quan, 2021 sourceExperimental — accuracy not yet measured
The Abstract and Conclusions say that an effective T. gondii vaccine for human or clinical use is unavailable. But the Introduction identifies Toxovax as a commercially available veterinary vaccine, so the unqualified claim that there is no safe and effective vaccine for T. gondii is broader than the paper supports. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the efficacy of different vaccine candidates cannot be compared because they were administered via different routes, animal types, vaccination doses, and vaccine production processes, all of which affect immunization efficacy (Zhang et al., 2022).”
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Discussion
What the sources say
- Partly supportedcites Zhang et al., 2022 sourceExperimental — accuracy not yet measured
The “Lack of standardized protocols for vaccines development” section (page unavailable) says that differing inoculation routes, doses, and animal models make candidate-vaccine efficacy difficult to compare. It does not say comparison is impossible or identify vaccine production processes as a reason. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, bioinformatics analysis on B and T cell epitopes revealed that TGGT1_316290 (TG290) had superior effects compared with the surface antigen 1 (SAG1).”
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nevertheless, all mice eventually died.”
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Notably, the IgG2a levels (0.86 ± 0.01, p < 0.0001, Figure 3B) were significantly higher than IgG1 level (0.47 ± 0.01, p < 0.0001, Figure 3B).”
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Results > TG290 mRNA-LNP facilitates the production of TG290-specific total IgG and subtype IgG1, IgG2a antibodies
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
38 more claims
Create a free account to see all 93 claims and to verify the 4 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 37
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Abstract
“The survival time of mice injected with TG290 mRNA-LNP was significantly longer (18.7 ± 3 days) compared with the survival of mice of the control groups (p < 0.0001).”
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Results > TG290 mRNA-LNP vaccination prolongs the survival time
“TG290 mRNA-LNP-vaccinated mice (Figure 8A, 18.5 ± 3 days, p < 0.0001) had prolonged survival time than mice in the blank and LNP groups (The mice in the two groups died within 8 days).”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Abstract
“In addition, adoptive immunization using 300 μl serum and lymphocytes (5*107) of mice immunized with TG290 mRNA-LNP significantly prolonged the survival time of these mice.”
§ A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice > Materials and methods > Immunization and Toxoplasma gondii challenge
“The mice were injected with TG290 mRNA-LNP-immunized splenocytes or LNP-immunized splenocytes, or naive splenocytes via the tail vein (5*108 splenocytes per mouse).”
Citations
Cites
Toxoplasma gondii: from animals to humans
Tenter, A. M., Heckeroth, A. R., & Weiss, L. M. (2000) · International Journal for Parasitology · doi:10.1016/s0020-7519(00)00124-7 · Cited by 3,702
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452
Montoya, J., & Liesenfeld, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16412-x · Cited by 3,232
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Epidemiology of and Diagnostic Strategies for Toxoplasmosis
Robert-Gangneux, F., & Dardé, M.-L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05013-11 · Cited by 1,815
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Zoonotic diseases: etiology, impact, and control
Rahman, M. T., Sobur, M. A., Islam, M. S., Ievy, S., Hossain, M. J., El Zowalaty, M. E., Rahman, A. T., & Ashour, H. M. (2020) · Microorganisms · doi:10.3390/microorganisms8091405 · Cited by 853 · cited 1×
“Vaccination can effectively prevent zoonoses (Rahman et al., 2020), especially mRNA vaccines since they have low insertional mutagenesis risk, safe delivery, low manufacturing cost, accelerated development cycles, and high potency.”
BackgroundThe Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design
Fleri, W., Paul, S., Dhanda, S. K., Mahajan, S., Xu, X., Peters, B., & Sette, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00278 · Cited by 500
Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and Presentation
Zhou, F. (2009) · International Reviews of Immunology · doi:10.1080/08830180902978120 · Cited by 456
Cited by
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 43
“A previous study [126] showed that mRNA vaccines have the ability to stimulate DC cell maturation.”
BackgroundSofroniou, A., & Ridley, A. (2025) · British Journal of Biomedical Science · doi:10.3389/bjbs.2025.14557 · Cited by 16
“In addition to the preventative mRNA vaccinations against infectious diseases reported in this systematic review there are preclinical trials with mRNA vaccines against Crimean-Congo haemorrhagic fever [117], Ebola [118] and toxoplasmosis [119].”
Hussein, H. A., Khaphi, F., Sivaramakrishnan, R., Poornima, S., & Abdullah, M. A. (2025) · Journal of Microencapsulation · doi:10.1080/02652048.2025.2495290 · Cited by 18
“2022, li et al. 2023).”
Wu, Q., Zhang, Z., Chu, H., Xia, B., Li, W., Ding, J., Ding, H., Zheng, B., Gao, M. Q., Wang, Y., et al. (2025) · Infectious Diseases of Poverty · doi:10.1186/s40249-025-01332-6 · Cited by 16
“Although it does not induce complete protection, the extended survival times induced by 4x-mRNA-LNP were somewhat satisfactory compared with certain single-antigen mRNA vaccines [45–47].”
Self-citationThe splicing factor SR2 is an important virulence factor of Toxoplasma gondii
(2023) · doi:10.3389/fmicb.2023.1302512 · Cited by 10
“IFA was performed as previously described (Li D. et al., 2023; Li T. T. et al., 2023).”
BackgroundMethodInfluential
Metadata
- Authors
- Li, D., Zhang, Y., Li, S., & Zheng, B.
- Affiliations
- Hangzhou Medical College (CN)
- Corresponding author
- Zheng, Bin
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-21
- Volume
- 14
- Pages
- 1145114-1145114
- ISSN
- 1664-302X (ISSN-L)
- PMC
- PMC10070739
- OpenAlex
- W4328114905
- Semantic Scholar
- f07e79832d1551e180e5e474b029176a17aa839f
- Cited by
- 22
- References
- 64
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 6 · 2023: 1
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (32000293)
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- Toxoplasma gondii, toxoplasmosis, mRNA-LNP vaccine, B and T cell epitopes, SAG1, humoral and cellular immune response, cytotoxic T lymphocytes, dendritic cell maturation, T-bet, NF-κB p65, IRF8, vaccine candidate, adoptive immunization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice. https://app.cochat.ai/papers/10.3389/fmicb.2023.1145114
- The paper
- Li, D., Zhang, Y., Li, S., & Zheng, B. (2023). A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2023.1145114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.